株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

エンテカビルの中国市場分析・予測

Investigation Report on China's Entecavir Market, 2018-2022

発行 China Research and Intelligence 商品コード 762938
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.74円で換算しております。
Back to Top
エンテカビルの中国市場分析・予測 Investigation Report on China's Entecavir Market, 2018-2022
出版日: 2019年01月01日 ページ情報: 英文 30 Pages
概要

当レポートでは、中国のエンテカビル市場について調査分析し、状況、市場規模、主要メーカー、市場競合、小売価格、市場の見通しについて、体系的な情報を提供しています。

第1章 エンテカビルの関連概念

  • エンテカビルの適応
  • 中国におけるエンテカビル開発の歴史
  • 中国におけるエンテカビルの政府承認

第2章 中国におけるエンテカビルの売上

  • 売上額
    • 総売上額
    • 売上額:地域別
  • 売上高
    • 総売上高
    • 売上高:地域別
  • 売上:剤形別
    • カプセル
    • タブレット

第3章 中国におけるエンテカビル主要メーカーの分析

  • 主要メーカーの市場シェア分析
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Sino-American Shanghai Squibb Pharmaceuticals Ltd.
  • Jiangxi Qingfeng Pharmaceutical Co., Ltd.
  • Suzhou Dawnrays Pharmaceutical Co., Ltd.
  • Fujian Cosunter Pharmaceutical Co., Ltd.

第4章 中国におけるエンテカビルの価格

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong)
  • Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude)
  • Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)
  • Suzhou Dawnrays Pharmaceutical Co., Ltd.. (Leiyide)
  • Fujian Cosunter Pharmaceutical Co., Ltd.(Enganding)

第5章 中国におけるエンテカビル市場の見通し

  • 市場発展に影響を与える要因の分析
  • 市場規模の予測
  • 市場動向の予測
目次
Product Code: 1901366

In China, more than 100 billion people are chronically infected with hepatitis B virus (HBV), of which 20 million to 30 million have chronic hepatitis B. It is estimated that every year, more than 500,000 people in China die of the liver damage or liver cancer caused by chronic hepatitis B, which leads to losses of over CNY 100 billion.

Developed by Bristol-Myers Squibb, Entecavir is a nucleoside analogue taken by mouth. In Mar. 2005, Entecavir was approved by the FDA. Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir was launched in China at the beginning of 2006 after being approved by the China Food and Drug Administration (CFDA) at the end of 2005. Later, Chinese pharmaceutical companies launched generic Entecavir successively, which drove the growth of the market.

According to CRI's market research, the annual sales value of Entecavir increased from over CNY 30 million in 2006 to CNY 2.03 billion in 2016, and decreased slightly in 2017. Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir still dominates the market. Its market share by sales value reached about 40% in 2017 but is shrinking as impacted by China-made generic drugs.

Entecavir has better and faster antiviral effect and see less side effects and drug resistance than traditional nucleoside analogs. Having a high genetic barrier to resistance, it is a powerful and long-acting HBV inhibitor for early monotherapy. As the demand for new anti-HBV drugs is far from being met, China's Entecavir market is promising with rising sales value in the coming years.

Topics Covered:

  • Development environment of China's Entecavir market
  • Size of China's Entecavir market
  • Competitive landscape of China's Entecavir market
  • Prices of Entecavir in China
  • Major factors influencing the development of China's Entecavir market
  • Prospect of China's Entecavir market

Table of Contents

1 Relevant Concepts of Entecavir

  • 1.1 Indications for Entecavir
  • 1.2 Development History of Entecavir in China
  • 1.3 Governmental Approval for Entecavir in China

2 Sales of Entecavir in China, 2013-2017

  • 2.1 Sales Value of Entecavir
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Entecavir
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Entecavir by Dosage Form in China, 2013-2017
    • 2.3.1 Entecavir Capsules
    • 2.3.2 Entecavir Tablets

3 Analysis on Major Entecavir Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Entecavir Manufacturers
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in China
  • 3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir in China
  • 3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd.
  • 3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd.
  • 3.6 Fujian Cosunter Pharmaceutical Co., Ltd.

4 Prices of Entecavir in China, 2017-2018

  • 4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong)
  • 4.2 Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude)
  • 4.3 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)
  • 4.4 Suzhou Dawnrays Pharmaceutical Co., Ltd. (Leiyide)
  • 4.5 Fujian Cosunter Pharmaceutical Co., Ltd. (Enganding)

5 Prospect of China's Entecavir Market, 2018-2022

  • 5.1 Factors Influencing Development of China's Entecavir Market
  • 5.2 Forecast on Size of China's Entecavir Market
  • 5.3 Forecast on Trend of China's Entecavir Market

Selected Charts

  • Chart Governmental Approval for Entecavir in China
  • Chart Sales of Entecavir in China, 2013-2017
  • Chart Sales Value of Entecavir in Parts of China, 2013-2017
  • Chart Sales Volume of Entecavir in China, 2013-2017
  • Chart Sales Volume of Entecavir in Parts of China, 2013-2017
  • Chart Sales Value of Entecavir Capsules in China, 2013-2017
  • Chart Sales Volume of Entecavir Capsules in China, 2013-2017
  • Chart Sales Value of Entecavir Tablets in China, 2013-2017
  • Chart Market Share of Top 5 Entecavir Manufacturers by Sales Value in China, 2013-2017
  • Chart Market Share of Top 5 Entecavir Manufacturers by Sales Volume in China, 2013-2017
  • Chart Sales Value of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir, 2013-2017
  • Chart Sales Volume of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir, 2013-2017
  • Chart Sales Value of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir, 2013-2017
  • Chart Sales Value of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir, 2013-2017
  • Chart Sales Value of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir, 2013-2017
  • Chart Sales Value of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir, 2013-2017
  • Chart Prices of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir (Runzhong) in Parts of China, 2017-2018
  • Chart Prices of Sino-American Shanghai Squibb Pharmaceuticals Ltd.'s Entecavir (Baraclude) in Parts of China in 2017
  • Chart Prices of Jiangxi Qingfeng Pharmaceutical Co., Ltd. 's Entecavir (Weiliqing) in Parts of China in 2017
  • Chart Prices of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir (Leiyide) in Parts of China in 2017
  • Chart Prices of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir (Enganding) in Parts of China in 2017
  • Chart Forecast on Sales Value of Entecavir in China, 2018-2022
Back to Top